Tivozanib for RCC: Efficacy, Safety, & Dose Optimization - Bradley McGregor, MD

2 Views

Thanks! Share it with your friends!

You disliked this video. Thanks for the feedback!

Published Apr 4, 2025

ARTICLE: https://oncologytube.com/tivozanib-for-rcc-unpacking-efficacy-safety-and-dose-optimization-bradley-mcgregor-md-dana-farber/

Join Dr. Bradley McGregor as he dives into the efficacy and safety exposure-response (ER) analysis of Tivozanib (TIVO) for renal cell cancer (RCC) treatment. This video explores key findings from clinical trials, including dose-dependent concentrations, the impact of hypertension, and strategies for optimizing TKI doses. Learn how Tivozanib stands out with its tolerability and why dose matters in improving patient outcomes. Perfect for medical professionals, researchers, or anyone interested in RCC treatment advancements!

Subscribe for more cutting-edge oncology insights, and hit the bell to stay updated!

Timestamps:
00:00 - Intro: Tivozanib Trial Analysis
00:03 - Building on Prior PK Models
00:16 - Navolaab and Hypertension Questions
00:38 - Dose-Dependent Concentrations
00:49 - Optimal Dose: 1.34 mg Findings
01:15 - Importance of TKI Dose Optimization
01:51 - Hypertension Management Tips
02:24 - Alliance Strike Trial Insights
02:53 - Contact 3 Trial Comparison
04:01 - Monotherapy Benefits of Tivozanib
04:33 - Future Directions: Strike Trial Support